Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.65 |
| ▸ | PDE4A | P27815 | 9/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.63 |
| ▸ | PDE1A | P54750 | 1/20 | 0.63 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.63 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332928 | 0.88 | PDE4D (0.79) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7423277 | 0.88 | PDE4D (0.78) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8197050 | 0.88 | PDE4D (0.82) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL985987 | 0.87 | PDE4D (0.63) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8188616 | 0.82 | PDE4D (0.63) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7688579 | 0.82 | POLB (0.57) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8185285 | 0.82 | SMN1; SMN2 (0.74) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7421935 | 0.81 | PDE4D (0.67) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7322708 | 0.81 | PDE4B (0.60) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL72993 | 0.81 | PDE4B (0.60) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5550137-A | Phenylaminocarbonyl derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-08-27 | — | — | US | claimed |
| EP-0607373-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS. | CELLTECH LTD (GB) | 1994-07-27 | — | — | EP | claimed |
| WO-1993025517-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS | CELLTECH LIMITED (GB) | 1993-12-23 | — | — | WO | claimed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-2049556-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | Basilea Pharmaceutica AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| US-6096747-A | Phenylaminocarbonyl derivatives and processes for their preparation | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| EP-0607373-B1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1997-03-19 | — | — | EP | disclosed |
| US-5550137-A | Phenylaminocarbonyl derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| WO-1995001335-A1 | NOVEL SPIROCYCLES | MERCK & CO., INC. (US) | 1995-01-12 | — | — | WO | disclosed |
| EP-0607373-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS. | CELLTECH LTD (GB) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993025517-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS | CELLTECH LIMITED (GB) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | POLB 2032/4885PDE4D 6/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.